MedTrace Logo

Evaluation of a Cincalcet Suppression Test

NCT01103206 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-16

No results posted yet for this study

Summary

The aim of the study is to compare the results of a parathyroid hormone (PTH)suppression test using a single oral tablet of cinacalcet in two groups of subjects: 1- a group of healthy adults in whom the results of the test with cinacalcet will be compared with those of the standardized PTH suppression test with intravenous calcium loading; 2- a group of patients with proven primary hyperparathyroidism in whom the results of the test with cinacalcet will be compared with those obtained during the same test, in healthy controls.

Conditions

  • Parathyroid Hormone Suppression Test With Cinacalcet

Interventions

DRUG

cinacalcet

Intake of a single tablet of cinacalcet

DRUG

cinacalcet dose 1

PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).

DRUG

cinacalcet dose 2

Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Jean Marc J Kuhn, MD · University Hospital of Rouen, France:

  • Anne F Cailleux, MD · University Hospital of Rouen, France:

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103206 on ClinicalTrials.gov